RBX 6610
Alternative Names: RBX-6610Latest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Ribometrix
- Class Antineoplastics; Small molecules
- Mechanism of Action Eukaryotic initiation factor 4E inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 16 Sep 2024 Pharmacodynamics and adverse events data from a preclinical trial in Non-small cell lung cancer released by Ribometrix
- 05 Sep 2024 RBX 6610 is available for licensing as of 05 Sep 2024. https://ribometrix.com/partnership/
- 05 Sep 2024 Preclinical trials in Non-small cell lung cancer in USA (PO), before September 2024